The combination mechanism of bevacizumab may enhance the anti-tumor activity of EGFR TKIs and perhaps increase intratumoral concentration of EGFR TKIs to partially reverse intrinsic resistance [79]. The gene discussed is EGFR; the disease is neoplasm.